参考文献/References:
[1]Kew MC.Hepatocellular carcinoma: epidemiology and risk factors[J].J Hepatocell Carcinoma,2014(1):115-125.
[2]Saad NS,Floyd K,Ahmed AA,et al.The Effect of Sorafenib, Tadalafil and Macitentan Treatments on Thyroxin-Induced Hemodynamic Changes and Cardiac Abnormalities[J].PLoS One,2016,11(4):e0153694.
[3]Keating GM.Sorafenib: A Review in Hepatocellular Carcinoma[J].Target Oncol,2017,12(2):243-253.
[4]Ye SL,Yang J,Bie P,et al.Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study[J].BMC Cancer,2018,18(1):247.
[5]Jackson R,Psarelli EE,Berhane S,et al.Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials[J].J Clin Oncol,2017,35(6):622-628.
[6]Bruix J,Raoul JL,Sherman M,et al.Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial[J].J Hepatol,2012,57(4):821-829.
[7]Weinmann A,Alt Y,Koch S,et al.Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma[J].BMC Cancer,2015(15):210.
[8]Pinyol R,Montal R,Bassaganyas L,et al.Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial[J].Gut,2018.
[9]Gao L,Wang X,Tang Y,et al.FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib[J].J Exp Clin Cancer Res,2017,36(1):8.
[10]Rimassa L,Assenat E,Peck-Radosavljevic M,et al.Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study[J].Lancet Oncol,2018,19(5):682-693.
[11]Santoro A,Rimassa L,Borbath I,et al.Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study[J].Lancet Oncol,2013,14(1):55-63.
[12]Bruix J,Tak WY,Gasbarrini A,et al.Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study[J].Eur J Cancer,2013,49(16):3412-3419.
[13]Bruix J,Qin S,Merle P,et al.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial[J].Lancet,2017,389(10064):56-66.
[14]Kudo M,Finn RS,Qin S,et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J].Lancet,2018,391(10126):1163-1173.
[15]Abou-Alfa GK,Meyer T,Cheng AL,et al.Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma[J].N Engl J Med,2018,379(1):54-63.
[16]Chau I,Park JO,Ryoo BY,et al.Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study[J].Br J Cancer,2018,119(1):19-26.
[17]Chen DS,Mellman I.Oncology meets immunology: the cancer-immunity cycle[J].Immunity,2013,39(1):1-10.
[18]Sangro B,Gomez-Martin C,de la Mata M,et al.A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C[J].J Hepatol,2013,59(1):81-88.
[19]Waidmann O.Recent developments with immunotherapy for hepatocellular carcinoma[J].Expert Opin Biol Ther,2018,18(8):905-910.
[20]Massard C,Gordon MS,Sharma S,et al.Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer[J].J Clin Oncol,2016,34(26):3119-3125.
[21]Finkelmeier F,Waidmann O,Trojan J.Nivolumab for the treatment of hepatocellular carcinoma[J].Expert Rev Anticancer Ther,2018,18(12):1169-1175.
[22]Kudo M,Finn RS,Qin S,et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J].Lancet, 2018,391(10126):1163-1173.
[23]Abou-Alfa GK,Qin S,Ryoo BY,et al.Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma[J].Ann Oncol,2018,29(6):1402-1408.
[24]Ikeda M,Kobayashi M,Tahara M,et al.Optimal management of patients with hepatocellular carcinoma treated with lenvatinib[J].Expert Opin Drug Saf,2018,17(11):1095-1105.
[25]Michot JM,Bigenwald C,Champiat S,et al.Immune-related adverse events with immune checkpoint blockade: a comprehensive review[J].Eur J Cancer,2016(54):139-148.
[26]Gao J,Shi LZ,Zhao H,et al.Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy[J].Cell,2016,167(2):397-404.
[27]史业辉,佟仲生.肿瘤免疫检查点抑制剂耐药机制及逆转耐药的相关治疗进展[J].中国肿瘤临床,2018,45(15):812-815.
[28]Cabibi D,Bisanti A,Lanza D,et al.Glypican-3 and Hep Par-1 are Useful Biomarkers in the Cytologic Assessment of Ascites[J].Appl Immunohistochem Mol Morphol,2018.
[29]Sawada Y,Yoshikawa T,Ofuji K,et al.Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients[J].Oncoimmunology,2016,5(5):e1129483.
相似文献/References:
[1]李书有.中晚期肝癌的非手术综合治疗[J].医学信息,2022,35(09):73.[doi:10.3969/j.issn.1006-1959.2022.09.018]
LI Shu-you.Non-surgical Comprehensive Treatment for Advanced Liver Cancer[J].Journal of Medical Information,2022,35(03):73.[doi:10.3969/j.issn.1006-1959.2022.09.018]
[2]吴玉斌,李先明.涎腺粘液表皮样癌与腺样囊性癌基因突变及靶向治疗研究[J].医学信息,2022,35(11):64.[doi:10.3969/j.issn.1006-1959.2022.11.018]
WU Yu-bin,LI Xian-ming.Study on Gene Mutation and Targeted Therapy of Mucoepidermoid Carcinoma and Adenoid Cystic Carcinoma of Salivary Gland[J].Journal of Medical Information,2022,35(03):64.[doi:10.3969/j.issn.1006-1959.2022.11.018]
[3]袁国辉,戴 超,吴兆平,等.CyclinA2基因多态性与肝细胞肝癌易感性的关系[J].医学信息,2018,31(22):77.[doi:10.3969/j.issn.1006-1959.2018.22.021]
YUAN Guo-hui,DAI Chao,WU Zhao-ping,et al.Relationship between Polymorphism of CyclinA2 Gene and Susceptibility to Hepatocellular Carcinoma[J].Journal of Medical Information,2018,31(03):77.[doi:10.3969/j.issn.1006-1959.2018.22.021]
[4]张文婧,宋 冰.HER-2阳性乳腺癌分子靶向治疗进展[J].医学信息,2018,31(24):42.[doi:10.3969/j.issn.1006-1959.2018.24.012]
ZHANG Wen-jing,SONG Bing.Progress in Molecular Targeted Therapy for HER-2 Positive Breast Cancer[J].Journal of Medical Information,2018,31(03):42.[doi:10.3969/j.issn.1006-1959.2018.24.012]
[5]牛 悦,白建平,卢建跃.HER-2阳性胃癌的研究进展[J].医学信息,2019,32(01):44.[doi:10.3969/j.issn.1006-1959.2019.01.015]
NIU Yue,BAI Jian-ping,LU Jian-yue.Progress in Research of HER-2 Positive Gastric Cancer[J].Journal of Medical Information,2019,32(03):44.[doi:10.3969/j.issn.1006-1959.2019.01.015]
[6]孙 峰,鲍扬漪,朱 婷,等.晚期结直肠癌抗血管生成靶向治疗研究进展[J].医学信息,2019,32(17):1.[doi:10.3969/j.issn.1006-1959.2019.17.001]
SUN Feng,BAO Yang-yi,ZHU Ting,et al.Advances in Anti-angiogenesis Targeted Therapy for Advanced Colorectal Cancer[J].Journal of Medical Information,2019,32(03):1.[doi:10.3969/j.issn.1006-1959.2019.17.001]
[7]穆红茹.中晚期宫颈癌的非手术治疗进展[J].医学信息,2022,35(15):167.[doi:10.3969/j.issn.1006-1959.2022.15.040]
MU Hong-ru.Advances in Nonsurgical Treatment of Cervical Cancer in the Middle and Late Stage[J].Journal of Medical Information,2022,35(03):167.[doi:10.3969/j.issn.1006-1959.2022.15.040]
[8]唐武兵,杨 文,陈健智,等.尼妥珠单抗联合调强适形放疗及化疗治疗局部晚期肺鳞癌的研究[J].医学信息,2019,32(20):1.[doi:10.3969/j.issn.1006-1959.2019.20.001]
TANG Wu-bing,YANG Wen,CHEN Jian-zhi,et al.Study of Nimotuzumab Combined with Intensity-modulated Radiotherapy and Chemotherapy in the Treatment of Locally Advanced Lung Squamous Cell Carcinoma[J].Journal of Medical Information,2019,32(03):1.[doi:10.3969/j.issn.1006-1959.2019.20.001]
[9]秦天宇,王立春.椎管内肿瘤手术方式的研究[J].医学信息,2019,32(22):35.[doi:10.3969/j.issn.1006-1959.2019.22.012]
QIN Tian-yu,WANG Li-chun.Study on Surgical Methods of Intraspinal Tumor[J].Journal of Medical Information,2019,32(03):35.[doi:10.3969/j.issn.1006-1959.2019.22.012]
[10]李芮蝶,朱雪莉,陈 鑫.三阴乳腺癌分型与临床药物治疗的研究[J].医学信息,2020,33(05):40.[doi:10.3969/j.issn.1006-1959.2020.05.013]
LI Rui-die,ZHU Xue-li,CHEN Xin.Study on the Classification of Triple Negative Breast Cancer and Clinical Drug Therapy[J].Journal of Medical Information,2020,33(03):40.[doi:10.3969/j.issn.1006-1959.2020.05.013]